Laboratory Corp Of America Holdings (NYSE:LH) Shifting Institutional Investors Sentiment

April 26, 2018 - By Migdalia James

Laboratory Corporation of America Holdings (NYSE:LH) Logo

Sentiment for Laboratory Corp Of America Holdings (NYSE:LH)

Laboratory Corp Of America Holdings (NYSE:LH) institutional sentiment increased to 1.2 in 2017 Q4. Its up 0.30, from 0.9 in 2017Q3. The ratio has improved, as 293 funds increased and opened new stock positions, while 245 decreased and sold their holdings in Laboratory Corp Of America Holdings. The funds in our partner’s database now possess: 91.47 million shares, down from 91.79 million shares in 2017Q3. Also, the number of funds holding Laboratory Corp Of America Holdings in their top 10 stock positions decreased from 14 to 13 for a decrease of 1. Sold All: 36 Reduced: 209 Increased: 220 New Position: 73.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory firm worldwide. The company has market cap of $17.62 billion. It operates through two divisions, LabCorp Diagnostics and Covance Drug Development. It has a 14.14 P/E ratio. The firm offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

The stock increased 3.99% or $6.63 during the last trading session, reaching $172.71. About 1.57M shares traded or 114.92% up from the average. Laboratory Corporation of America Holdings (NYSE:LH) has risen 14.17% since April 26, 2017 and is uptrending. It has outperformed by 2.62% the S&P500.

Veritas Investment Management Llp holds 6.79% of its portfolio in Laboratory Corporation of America Holdings for 307,591 shares. Bridger Management Llc owns 633,162 shares or 6.67% of their US portfolio. Moreover, Healthinvest Partners Ab has 5.99% invested in the company for 17,800 shares. The New York-based Healthcor Management L.P. has invested 5.71% in the stock. Allen Investment Management Llc, a New York-based fund reported 769,875 shares.

Since January 1, 0001, it had 0 insider buys, and 5 selling transactions for $10.55 million activity.

Laboratory Corporation of America Holdings (NYSE:LH) Ratings Coverage

Ratings analysis reveals 71% of Laboratory Corp’s analysts are positive. Out of 14 Wall Street analysts rating Laboratory Corp, 10 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $165.0 while the high is $210. The stock’s average target of $193.29 is 11.92% above today’s ($172.71) share price. LH was included in 21 notes of analysts from November 24, 2017. The stock of Laboratory Corporation of America Holdings (NYSE:LH) earned “Hold” rating by Jefferies on Tuesday, March 6. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, February 6 report. The company was maintained on Wednesday, February 28 by Morgan Stanley. Mizuho maintained the shares of LH in report on Wednesday, January 24 with “Hold” rating. The firm has “Hold” rating given on Monday, December 11 by Credit Suisse. The firm has “Buy” rating given on Thursday, January 11 by SunTrust. SunTrust maintained the stock with “Buy” rating in Wednesday, February 28 report. The firm has “Buy” rating given on Wednesday, February 28 by Canaccord Genuity. The company was maintained on Friday, December 1 by Mizuho. The firm has “Buy” rating by Craig Hallum given on Wednesday, February 7.

Laboratory Corporation of America Holdings (NYSE:LH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: